MENSINGDERMAresearch GmbH
- Address
- lock Available on a paid plan
Immune System Diseases
The work at MENSINGDERMAresearch GmbH concentrates on immune system disorders, notably atopic dermatitis and chronic spontaneous urticaria, aiming to test new biologic agents and assess their long‑term safety.
- Novel biologics for skin‑related immune inflammation
- Extended safety monitoring across dose regimens
- Comparative efficacy versus standard care
- Exploration of immune‑pathway biomarkers
- Evaluation of patient‑reported outcome tools
With six active studies and three investigators, the site in Hamburg advances therapeutic options for patients suffering from challenging immune‑mediated skin conditions.
Skin and Connective Tissue Diseases
Research at this Hamburg clinic addresses skin and connective tissue diseases such as moderate‑to‑severe plaque psoriasis and various forms of dermatitis, focusing on the development and testing of innovative treatment strategies.
- Targeted therapies for plaque psoriasis
- Dose‑ranging investigations to optimize efficacy
- Biomarker discovery for treatment response
- Real‑world effectiveness and quality‑of‑life assessments
- Combination approaches with existing standards
The centre’s six clinical trials reflect a commitment to improving outcomes for patients with severe skin disorders, leveraging expertise from three dedicated investigators.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 18 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Janssen Cilag International1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MENSINGDERMAresearch GmbH
lock Showing 1 of 10 trials — the rest is available on a paid plan.
IMP list
lock Showing 1 of 18 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Humanised Igg1 Kappa Monoclonal Antibody Against Interleukin 18 | 2 | Unknown | 2024-04-10 | 2024-10-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.